Are pharmaceutical makers becoming Outcomes companies?

Population Health
Written By Matthew Hanis

Andrew 'AJ' Ploszay, Ph.D.

Head of Digital Innovation
GlaxoSmithKline

Brad Ansley

Managing Partner
SPI Health

Digital is disrupting pharmaceutical companies at their very core: product development and commercial operations. We explore this with two leaders deep in the thick of transforming this key healthcare segment . . . 10% of the overall healthcare spend in the US . . . as digital innovation destroys and recreates the industry. AJ Ploszay leads digital innovation at GlaxoSmithKline and Brad Ansley leads the healthcare practice at SPI.

Matthew Hanis
Previous

CCBHC Pilots & Whole Patient Care
Next

Turning 33,000 employees into an agile pharma start-up